Advanced Filters
noise

Alzheimer's Disease Clinical Trials

A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 806 clinical trials

Monitoring Drug Efficacy in Patients with Alzheimer's Disease

This study will explore the different factors associated with drug response to acetylcholinesterase (AChE) inhibitor (donepezil) and NMDA receptor antagonist (memantine) in patients with Alzheimer's Disease.

65 years of age All Phase N/A
D Diana S. Guzman

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, …

50 years of age All Phase 2
E Eva Wu

Gamma-Music Based Intervention for Mild Alzheimer's Disease

The study will test and refine a novel brain-stimulation tool using gamma-frequency lights coupled with self-selected music for a gamma-music-based intervention for participants with mild Alzheimer's Disease. Results will yield a gamma-stimulation protocol that reliably influences brain activity (Aim 1), is adaptive, motivating and rewarding to use (Aim 2), and …

50 - 95 years of age All Phase N/A

Cognitive Neurology Unit Clinical Registry

A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease

50 - 95 years of age All Phase N/A
H Hamid Okhravi, MD

Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to 1) determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants and 2) determine whether THC-free CBD oil can reduce the burden on caregivers and increase the participants' quality of life.

50 - 90 years of age All Phase 2
C Cristina Toedebusch, BS

DORA and LP in Alzheimer's Disease Biomarkers

The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.

65 years of age All Phase 2
C CRISTIAN RIPOLI

Next-Generation alzheImer'S Therapeutics

Is this the right time to use next-generation approaches in Alzheimer's disease (AD)? In recent years, several large clinical trials testing treatments for AD have failed, putting the entire field on a reset. AD drug trials have almost exclusively sought to use antibodies targeted toward misfolded amyloid and tau proteins. …

18 - 80 years of age All Phase N/A
A Anne Mortensen

Dementia Care Partner Hospital Assessment Tool

The purpose of this study is to see whether an adapted questionnaire called the Care Partner Hospital Assessment Tool (CHAT) for care partners of hospitalized patients living with Alzheimer's disease and related dementias (ADRD) (CHAT-AD) can help people with dementia receive better care after they go home from the hospital. …

18 years of age All Phase N/A
T Timothy Kwok, MD

Cognitive Decline in AD

There is lack of information on the risk factors of accelerated cognitive decline in older people with Alzheimer disease (AD). The extent of neurodegeneration and white matter disease has been reported to be important factors. In addition there may be biomarkers e.g. inflammatory cytokines that can contribute to cognitive decline. …

65 - 92 years of age All Phase N/A
R Rajagopal V Sekhar, MD

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the effects of supplementing glycine and N-acetylcysteine vs. alanine as placebo on these defects in AD, and examine …

55 - 85 years of age All Phase 0

Simplify language using AI